Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05533697 · ClinicalTrials.gov registry record · Phase 1
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 361
- Enrollment target
- 20
- Study locations
NCT05533697 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 361 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (84% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT05533697, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 361 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- BIOLOGICAL mRNA-4359
Study Locations (20)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
New South Wales
- Southside Cancer Center - Miranda
- Melanoma Institute Australia - Wollstonecraft
Other
- NEXT Oncology Barcelona - Barcelona
- NEXT Oncology Madrid - Madrid
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Colorado
- University of Colorado Cancer Center - Aurora
District of Columbia
- George Washington University - Washington D.C.
Florida
- Orlando Health UF Health Cancer Center - Orlando
Illinois
- The University of Chicago Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 361 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2032-02-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05533697
The ClinicalTrials.gov registry entry for NCT05533697 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 361 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (84% higher). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05533697 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Massachusetts, New South Wales, Other.
Frequently Asked Questions
What is clinical trial NCT05533697 about?
NCT05533697 is a clinical study titled "Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors". The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
What is the current status of trial NCT05533697?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 361 participants. The study started on 2022-09-01. Estimated completion is 2032-02-18.
What conditions does trial NCT05533697 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT05533697?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), mRNA-4359 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05533697?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05533697 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.